It depends on the standard you follow. As of September 2026, Travere Therapeutics, Inc. (TVTX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 11.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.69% / 30% · Interest income / Revenue 1.65% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 11.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.69% / 33% · Receivables / Mkt Cap (36m) 1.98% / 49% · Interest income / Revenue 1.65% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 11.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.69% / 33.33% · Receivables / Mkt Cap (24m) 1.98% / 33.33% · Interest income / Revenue 1.65% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 66.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 55.1% / 33.33% · Receivables / Avg Assets (4Q) 12.7% / 33.33% · Interest income / Revenue 1.65% / 5% | Fail |
| FTSE | Debt / Total Assets 71.1% / 33.33% · (Cash+ST Inv) / Total Assets 55.6% / 33.33% · (Cash+Recv) / Total Assets 68.3% / 33.33% · Interest income / Revenue 1.65% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Travere Therapeutics, Inc. (TVTX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Travere Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.65% of each dividend: Travere Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a Healthcare company (Biotechnology) with a market capitalization of $4.8B. The Maz Rating grades it against the other companies in its sector.
Travere Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $49.70, Travere Therapeutics, Inc. trades at 7.3x sales and 208.2x book value. Over the last twelve months it generated about $651M of revenue and a net loss of $150M. It runs a gross margin of 94.7%, an operating margin of -20.5% and a net margin of -18.7%. It shows return on equity of -186.5%, return on invested capital of -20.1% and a free cash flow yield of 2.8%. On the balance sheet: a debt-to-equity ratio of 27.28 and a current ratio of 3.00. Over the past 52 weeks the share price ranged from $22.59 to $68.73, with a beta of 1.12.
Travere Therapeutics, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 15 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.